Q3 EPS Forecast for Revolution Medicines Cut by Analyst

Revolution Medicines, Inc. (NASDAQ:RVMD) – HC Wainwright lowered their Q3 2026 earnings per share estimates for Revolution Medicines in a research note issued on Thursday, August 27th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($2.42) for the quarter, down from their prior estimate of ($2.07). HC Wainwright has a “Buy” rating and a $280.00 price target on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($8.84) per share. HC Wainwright also issued estimates for Revolution Medicines’ Q4 2026 earnings at ($2.23) EPS and FY2026 earnings at ($9.20) EPS.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same quarter in the previous year, the business posted ($1.31) earnings per share.

RVMD has been the subject of a number of other research reports. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $248.00 price objective on shares of Revolution Medicines in a report on Thursday, August 27th. TD Cowen raised shares of Revolution Medicines to a “strong-buy” rating in a report on Monday, August 24th. UBS Group raised their price target on shares of Revolution Medicines from $220.00 to $265.00 and gave the stock a “buy” rating in a research report on Friday. Mizuho lifted their price target on shares of Revolution Medicines from $185.00 to $215.00 and gave the company an “outperform” rating in a report on Monday, July 6th. Finally, Evercore reaffirmed an “outperform” rating and set a $320.00 price objective on shares of Revolution Medicines in a research report on Thursday, August 27th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $200.74.

Revolution Medicines Price Performance

Shares of NASDAQ RVMD opened at $209.87 on Monday. The company has a current ratio of 11.38, a quick ratio of 11.38 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $44.98 billion, a price-to-earnings ratio of -23.79 and a beta of 1.40. Revolution Medicines has a twelve month low of $37.88 and a twelve month high of $224.31. The business has a 50 day simple moving average of $194.93 and a 200-day simple moving average of $150.51.

Insider Buying and Selling at Revolution Medicines

In other news, CFO Jack Anders sold 20,000 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $168.33, for a total transaction of $3,366,600.00. Following the completion of the transaction, the chief financial officer owned 123,269 shares in the company, valued at approximately $20,749,870.77. This represents a 13.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Margaret A. Horn sold 60,400 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $160.17, for a total transaction of $9,674,268.00. Following the completion of the sale, the chief operating officer directly owned 158,222 shares in the company, valued at approximately $25,342,417.74. This trade represents a 27.63% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 212,497 shares of company stock valued at $38,206,486. Corporate insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Revolution Medicines

A number of hedge funds have recently made changes to their positions in the business. Meeder Advisory Services Inc. boosted its position in shares of Revolution Medicines by 3.0% during the first quarter. Meeder Advisory Services Inc. now owns 4,126 shares of the company’s stock worth $401,000 after buying an additional 120 shares during the period. PNC Financial Services Group Inc. raised its stake in shares of Revolution Medicines by 1.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 10,066 shares of the company’s stock valued at $802,000 after purchasing an additional 125 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in Revolution Medicines by 147.7% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 218 shares of the company’s stock worth $41,000 after purchasing an additional 130 shares during the period. Deutsche Bank AG lifted its holdings in Revolution Medicines by 0.4% in the fourth quarter. Deutsche Bank AG now owns 32,217 shares of the company’s stock worth $2,566,000 after purchasing an additional 130 shares during the period. Finally, Contravisory Investment Management Inc. bought a new position in Revolution Medicines in the 2nd quarter valued at about $32,000. Institutional investors own 94.34% of the company’s stock.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.